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Optimal therapy of patients with steroid-resistant primary
focal segmental glomerulosclerosis (FSGS) remains
controversial. This report describes the initial study design,
baseline characteristics, and quality of life of patients
enrolled in the FSGS Clinical Trial, a large multicenter
randomized study of this glomerulopathy comparing a
12-month regimen of cyclosporine to the combination of
mycophenolate mofetil and oral dexamethasone. Patients
with age ranging 2–40 years, with an estimated glomerular
filtration rate 440ml/min per 1.73m2, a first morning urine
protein-to-creatinine ratio over one, and resistant to
corticosteroids were eligible. The primary outcome was
complete or partial remission of proteinuria over 52 weeks
after randomization. In all, 192 patients were screened, of
whom 138 were randomized for treatment. Ethnic
distributions were 53 black, 78 white, and 7 other. By self- or
parent-proxy reporting, 26 of the 138 patients were
identified as Hispanic. The baseline glomerular filtration
rate was 112.4 (76.5, 180.0) ml/min per 1.73m2, and urine
protein was 4.0 (2.1, 5.3) g/g. Overall, the quality of life of the
patients with FSGS was lower than healthy controls and
similar to that of patients with end-stage renal disease.
Thus, the impact of FSGS on quality of life is significant
and this measurement should be included in all trials.
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Focal segmental glomerulosclerosis (FSGS) can be a primary
glomerular disorder or develop secondary to a variety of
insults.1 Primary FSGS can arise as a consequence of genetic
mutations in structural podocyte proteins2 or reflect the
presence of unidentified immunologic abnormalities that
increase glomerular permeability to protein.3 The diagnosis
of FSGS is contingent on demonstrating the presence of
segmental sclerosis within the glomerular tuft.4,5
The initial treatment of primary FSGS in children and
young adults usually involves corticosteroids.6,7 Approxi-
mately 25% of patients with primary FSGS respond to an
initial course and enter remission.8–10 Patients who are
steroid resistant have a chronic disease and are at increased
risk of progressing to end-stage kidney disease (ESKD),6,8,11
complications related to uncontrolled nephrotic syndrome,
and impaired quality of life.
The optimal therapy of patients with steroid-resistant
primary FSGS remains controversial.7 Many agents have been
evaluated, including methylprednisolone, cyclophosphamide,
mycophenolate mofetil (MMF), calcineurin inhibitors, and
rituximab, but not in randomized trials.12,13 The only
medication that has been evaluated in well-designed clinical
trials and has shown to increase the rate of partial and
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complete remission is cyclosporine (CSA).14,15 The high
relapse rate following discontinuation of CSA14 and side-
effect profile, including risk for nephrotoxicity and cosmetic
effects, has stimulated a desire for an alternative treatment
regimen in FSGS.
Extended and continuous exposure to corticosteroids
improves the complete and partial remission rates in patients
with FSGS in observational studies and uncontrolled trials.
Kopp et al. (J Kopp, NIDDK, personal communication)
evaluated pulse oral dexamethasone 25mg/m2 administered
days 1–4 of each 28-day cycle and repeated over 32 weeks in
15 adults with idiopathic FSGS and proteinuria X3.5 g/day.
One patient entered complete remission (urine protein/
creatinine ratio (Up/c) o0.3 g/g) and six patients entered
partial remission (Up/c o2 g/g), for an overall response rate
of 47%. The sustained response rate fell to 20% with longer
follow-up (J Kopp, NIDDK, personal communication, and
presented in abstract in Smith et al.16). Uncontrolled data
from a single-center suggest improved control of FSGS with
long-term pulse corticosteroid therapy in conjunction with
cytotoxic agents if the response to corticosteroids alone was
insufficient.17 MMF may reduce urine protein excretion in
steroid-dependent and steroid-resistant patients with FSGS
with a better side-effort profile compared with CSA and
cytotoxic agents.18,19 Nonetheless, all of the above agents and
regimens have significant side effects, which spur interest in
the development of new therapies for FSGS.
The National Institutes of Health-funded FSGS Clinical
Trial (FSGS CT) was a multicenter randomized clinical trial
comparing the efficacy of a 12-month course of CSA to a
combination of oral pulse dexamethasone and MMF in
children and adults with steroid-resistant FSGS. The
objectives of this article are to: (1) document the trial design;
(2) describe the baseline clinical and laboratory features; and
(3) evaluate the quality of life (QOL) in the FSGS CT cohort.
RESULTS
Enrollment into the trial commenced on 9 November 2004
and the last follow-up visit in the treatment phase of the
study was completed on 30 November 2009. A total of 192
patients were enrolled and screened for the FSGS CT; 54
patients were excluded and 138 were randomized. The most
common reasons for screen failure were Up/c ratio o1 g/g
(n¼ 20) and a kidney biopsy that was inconsistent with
primary FSGS (n¼ 18; Figure 1). Other causes for exclusion
included previous therapy with one of the study agents
(n¼ 1); ineligible age (n¼ 1); study team recommendation
(n¼ 1); and acute kidney injury (n¼ 1). Age, race, ethnicity,
and proteinuria were similar in the screened and randomized
groups.
Randomized sample
The 138 randomized subjects were evenly distributed
between three age categories: 2–12, 13–17, and 18–40 years.
The racial and ethnic distribution was diverse, with 38.4%
(n¼ 53) black, 56.5% (n¼ 78) white, 5.1% (n¼ 7) other
races, and 18.8% (n¼ 26) Hispanic. Of the patients, 65
(47.1%) were female.
The subjects were diagnosed with FSGS 6.7 (3.6, 16.2)
months before enrollment (range 1.0–131.1 months). Cumu-
lative time of corticosteroid exposure at study entry was 3.0
(2.0, 6.0) months with no difference between adult and child
participants (P¼ 0.84; Table 1). The number of previous
courses of steroids was not recorded and the distinction
between primary versus secondary steroid resistance was not
distinguished in trial participants. At screening, 58% (n¼ 80)
of subjects had hypertension by history and 20.3% (n¼ 28)
had office blood pressure measurements in the hypertensive
range. Antihypertensive therapy was prescribed for 81.2% of
the patients (n¼ 112), including 72.5% (n¼ 100) angioten-
sin-converting enzyme inhibitor (ACEI) or angiotensin
receptor blocker and 8.7% (n¼ 12) other classes of agents.
Signs and symptoms
Edema was present on examination in 57.3% (n¼ 79) of
subjects and was most often pretibial in 29.0% of the cohort.
It was a symptom at disease onset in 67.0% of the children
and 65.9% of the adults. Other symptoms reported within
2 weeks of enrollment included cough 26.8% (n¼ 37), nausea
19.6% (n¼ 27), orthostatic symptoms 18.8% (n¼ 26),
diarrhea 18.8% (n¼ 26), and emesis 13.0% (n¼ 18).
Laboratory and pathology findings
The subjects had an estimated glomerular filtration rate (eGFR)
of 112.4 (76.5, 180.0) ml/min per 1.73m2 (range: 37.6–408.8)
and Up/c of 4.0 (2.1, 5.3) g/g (range: 1.0–31.8; Table 1). Serum
albumin was lower and total and low-density lipoprotein
cholesterol higher in children compared with adults. Only eight
participants had anemia with a hemoglobin levelo11 g/dl. The
collapsing variant of FSGS was present in 11.6% (n¼ 16) of
subjects, and histology subtypes were not different by age
group. There were 11 randomized patients in whom the
diagnosis of FSGS was made 41 year before enrollment. The
histological subtypes of FSGS were not different in this group
compared with the remaining 127 patients (P¼ 0.18).
Patients enrolled
N = 192
Patients randomized
N = 138
Patients excluded
N = 54
• Urine protein/cr (Up/c)  <1: n = 20
• Biopsy not FSGS: n = 18
• eGFR <40: n = 5
• Consent withdrawn: n = 4
• Malignancy Hx: n = 1
• Uncontrolled HTN: n = 1
• Not steroid resistant: n = 1
• Others: n = 4
Figure 1 | Focal Segmental Glomerulosclerosis (FSGS) Clinical
Trial enrollment, screening, and randomization summary.
eGFR, estimated glomerular filtration rate; HTN, hypertension; Hx,
history; Up/c, urine protein/creatinine ratio.
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Medical and family history
Premature birth was reported by 13% of subjects. Past,
passive, and current smoking exposure was reported by 6.5%
(n¼ 9), 15.9% (n¼ 22), and 7.3% (n¼ 10), respectively.
Adults were more likely to have had exposure to tobacco
compared with children (51.2 vs 20.6%, P¼ 0.003). Other
health conditions were uncommon and did not differ by age,
including 2.2% (n¼ 3) thromboembolic events, 5.1% (n¼ 7)
seizures, 5.8% (n¼ 8) attention deficit disorder, and 2.9%
(n¼ 4) insomnia or other sleeping disorders. Subjects had a
cumulative family history of proteinuria, FSGS, kidney
disease, and ESKD of 10% (n¼ 14).
Quality of life
Children in FSGS CT compared with controls. The health-
related QOL in child participants was reported by parents
and patients and compared with published results from
healthy and ESKD populations20,21 (Table 2). Compared with
healthy controls, children with FSGS and their parents
independently reported a lower total QOL score and in the
specific domains of Physical, Emotional, and School
Functioning. The only domain in which children and parents
in the FSGS cohort reported scores comparable to healthy
controls was Social Functioning. In contrast, children and
parents in the FSGS CT reported QOL scores comparable to
the ESKD group, except for the Social Functioning domain,
in which the FSGS patients had higher values than the ESKD
cohort. Parents reported better School Functioning QOL but
the children did not report significantly different School
Functioning than their ESKD peers. In the overall QOL score
and the Physical and Emotional Functioning domains, the
FSGS CT QOL results were similar to the ESKD cohort.
Adults in FSGS CT compared with controls. Adults with
FSGS reported a lower QOL than healthy controls in the
Mental Health and Physical Health composite scores and the
domains of Mental Health, Vitality, General Health, Role
Table 1 | Cohort baseline characteristics
Variable
Children o18
(n=93)
Adults 418
(n=45) P-value
Age 13 (2, 15) 31 (25, 35) o0.0001
Female 44 (47.3%) 21 (46.7%) 0.94
eGFR (ml/min per 1.73m2) o0.0001
40–60 7 (7.5%) 9 (20.0%)
61–75 4 (4.3%) 8 (17.8%)
76–90 6 (6.5%) 14 (31.1%)
91–120 18 (19.4%) 9 (20.0%)
4120 58 (62.4%) 5 (11.1%)
Up/c (g/g) 0.06
1–1.99 18 (19.3%) 15 (33.3%)
2–3.99 21 (22.6%) 15 (33.3%)
4–7.99 24 (25.8%) 7 (15.6%)
8+ 30 (32.3%) 8 (17.8%)
Albumin (g/dl) 2.7 (2, 3.5) 3.6 (2.7, 3.8) 0.006
Cholesterol, total (mg/dl) 318 (264, 484)a 261 (230, 368.5)f 0.01
Cholesterol, LDL (mg/dl) 184 (147, 275)b 152 (121, 203)g 0.04
Cholesterol, HDL (mg/dl) 64 (48, 89)a 69.5 (50.5, 93.5)f 0.94
Hemoglobin (anemia levels) 0.91
o11 5 (5.4%) 3 (6.7%)
11–12 5 (5.4%) 3 (6.7%)
X12 83 (89.3%) 39 (86.7%)
FSGS pathology subtype 0.25
NOS 68 (73.1%) 26 (57.8%)
Perihilar 6 (6.5%) 4 (8.9%)
Cellular 1 (1.1%) 3 (6.7%)
Tip 8 (8.6%) 6 (13.3%)
Collapsing 10 (10.8%) 6 (13.3%)
Duration of FSGS (months) 6.4 (2.9, 12.1) 12.3 (5.4, 19.7) 0.12
Previous steroid exposure
(months)
3 (2, 4)c 4 (2, 6)h 0.84
Hypertension 49 (52.7%) 31 (68.9%) 0.07
Premature birth 15 (16.1%) 3 (6.7%) 0.24
Smoking exposure 0.0001
Former smoker 2 (2.1%) 7 (15.6%)
Passive smoker 17 (18.3%) 5 (11.1%)
Current smoker 0 (0.0%) 10 (22.2%)
Thrombotic events 1 (1.1%) 2 (4.4%)h 0.15
Family history
Proteinuria 3 (3.4%)a 5 (12.2%)i 0.14
FSGS 2 (2.3%)d 1 (2.4%)j 0.95
Kidney disease 5 (5.6%)e 7 (15.9%)h 0.03
ESKD 3 (3.4%)e 4 (9.8%)h 0.31
Abbreviations: eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney
disease; FSGS, focal segmental glomerulosclerosis; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; NOS, not otherwise specified; Up/c, urine protein/
creatinine ratio.
Continuous variables are presented as median (interquartile range).
Numbers of subjects: a=87; b=71; c=83; d=88; e=89; f=40; g= 35; h=44; i=41;
and j=42.
Table 2 | QOL assessment of children with steroid-resistant
FSGS compared with healthy and ESKD controls
FSGS CT ESKDa Healthyb
N Mean s.d. N Mean s.d. N Mean s.d.
Physical functioning
Parentc,d 94 73.5 26.0 186 68.24 24.09 9430 84.48 19.51
Childc 80 77.7 19.1 190 74.97 19.37 5480 87.53 13.50
Emotional functioning
Parentc 94 66.2 22.1 188 68.93 21.13 9430 81.31 16.50
Childc 80 71.0 19.0 190 72.53 20.80 5480 79.33 18.15
Social functioning
Parentd 94 81.1 20.6 188 70.43 23.77 9430 83.70 19.43
Childd 80 85.3 16.5 189 77.80 20.96 5480 85.15 16.76
School functioning
Parentc,d 89 70.0 20.8 181 59.16 25.04 9430 78.83 19.59
Childc 80 69.8 17.7 188 63.57 22.18 5480 81.12 16.45
Total score
Parentc,d 94 72.7 17.8 186 67.02 19.84 9430 82.70 15.40
Childc 80 76.0 13.3 190 72.53 16.16 5480 83.84 12.65
Abbreviations: ESKD, end-stage kidney disease; FSGS CT, Focal Segmental
Glomerulosclerosis Clinical Trial; QOL, quality of life.
aGoldstein, 2008.21
bVarni, 2007.20
cFSGS oHealthy, P=0.00005 to Po0.0000.
dFSGS 4ESKD, P=0.05–0.00005.
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Physical, and Social Functioning. Compared with the ESKD
group, the FSGS cohort reported a worse Mental Health
composite score but a better Physical Health composite score.
FSGS and ESKD cohort QOL scores were similar in the
domains of Mental Health, Vitality, Role Emotional, and
Social Functioning22,23 (Table 3).
DISCUSSION
This report provides the FSGS CT design and details the key
clinical and laboratory features, compares the demographic
and disease-related characteristics between children and
adults, and presents QOL results from patients with
steroid-resistant FSGS at the time of trial enrollment. The
majority of trial patients were p18 years of age (70%). The
trial includes a high representation of Black and Hispanic
patients, comparable with other cohorts and studies of FSGS
in the United States.24,25 The eGFR was well preserved in trial
participants, consistent with the eligibility criterion of an
eGFR X40ml/min per 1.73m2.
The pediatric and adult patients had similar cumulative
steroid exposure before the study, socioeconomic status, level
of proteinuria, degree of edema, and underlying FSGS
histopathology subtype. However, in children and adoles-
cents, the eGFR was higher, the prevalence of hypertension
was lower, and the severity of the metabolic features of the
nephrotic syndrome, that is, hypoalbuminemia and hyper-
cholesterolemia, was worse than in adult patients. These
observations coincide with previous studies and suggest that
the nature of primary steroid-resistant FSGS may vary with
age. After the design of this trial, Branten et al.26 reported
that tubular secretion of creatinine increases with hypoalbu-
minemia. In patients with nephrotic syndrome and hypoal-
buminemia, creatinine-based equations overestimate the
GFR determined by inulin clearance. The lower serum
albumin in the pediatric trial subjects may contribute to
the higher calculated eGFR in children.
Assessment of health-related QOL has become a standard
component in the clinical evaluation of patients with a
variety of chronic diseases. It has been incorporated into the
predefined end points in many clinical trials to enable a more
comprehensive determination of relevant clinical outcomes
in response to the experimental intervention. QOL has been
assessed in cohort studies in children with steroid-sensitive
nephrotic syndrome, in all ages with chronic kidney disease
(CKD), and in adults with autosomal dominant polycystic
kidney disease but not in steroid-resistant FSGS.21,27–30
Children with steroid-sensitive nephrotic syndrome have
been shown to have a diminished health-related QOL. In a
study of 45 children, patient self-reports suggested that only
the Social Functioning domain was impaired relative to
healthy controls. Parents of these children report a more
significant reduction in health-related QOL in the Social,
Emotional, Motor, and Cognition domains. Factors asso-
ciated with QOL impairment were steroid dependency,
cytotoxic therapy, and maternal stress.31
Patients with CKD requiring renal replacement therapy
have demonstrated reduced QOL scores in Physical, Emo-
tional, and Social Function.21,27,32,33 There have been fewer
large-scale studies of patients with CKD before dialysis
treatment.28,29 In a recent study of 1186 adults with CKD,
QOL declined progressively with more advanced stages of
kidney disease.33 Lower QOL scores predict a higher
mortality in adults with CKD, irrespective of whether or
not they are receiving renal replacement therapy.21,27,29,33
The baseline findings in the FSGS CT cohort indicate a
significant impairment in QOL compared with healthy
controls. Children showed impairment in all measured
domains except Social Functioning. Adults in the FSGS CT
had lower scores in Mental Health and Physical Health
composite assessments and in specific domains including
Social Functioning. Across the entire age spectrum, patients
with FSGS had QOL scores that were comparable with patients
Table 3 | SF-36 QOL comparison of FSGS CT adult subjects compared with ESRD and general US population controls
FSGS, N=43 ESKD, N=1896a Healthy, N=2474b
Mean s.d. Mean s.d. Mean s.d.
Mental health (MH)c 72.2 18.7 71.6 19.3 84.2 18.1
Vitality (VT)c 47.8 24.9 50.0 21.8 60.9 21.0
General health (GH)c,d 50.6 10.4 46.3 21.2 72.0 20.3
Bodily pain (BP)d 72.3 27.3 62.8 27.9 75.2 23.7
Physical functioning scale (PF)d,e 77.6 26.7 48.1 26.9 84.2 23.3
Role, emotional (RE) 71.3 42.2 63.8 41.9 81.3 33.0
Role, physical (RP)c,d 65.3 43.2 44.0 40.5 81.0 34.0
Social functioning (SF)c 75.9 28.4 70.6 27.0 83.3 22.7
Mental health composite t-score (MH)c,f 44.1 12.6 49.9 10.9 50.0 10.0
Physical health composite t-score (PH)3c,d 44.3 10.3 35.7 10.1 50.0 10.0
Abbreviations: ESKD, end-stage kidney disease; ESRD, end-stage renal disease; FSGS CT, Focal Segmental Glomerulosclerosis Clinical Trial; QOL, quality of life; SF-36, Short
Form-36.
aUnruh, 2004.22
bWare, 2003.23
cFSGS oHealthy, P=0.09 to o0.000001.
dFSGS 4ESKD, P=0.01 to o0.00001.
eBased on 42 FSGS trial subjects.
fFSGS oESKD, P=0.001.
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with ESKD. Longitudinal assessment of QOL in response to the
two study treatments in the FSGS CT will provide important
information on the effect of specific therapies.
This trial includes children and adults because new
therapeutic options are necessary across this age span and
are often chosen based upon the diagnosis rather than the age
of the patient. The upper age of 40 years and exclusion of
significant coexisting conditions were established as eligibility
criteria to decrease the likelihood of secondary or multiple
causes of kidney disease. Inclusion of a wide age span adds
specific challenges to the design and analysis of a trial. GFR-
estimating equations and QOL assessment tools have been
generated separately for children and adults. These metho-
dological disconnects force the analysis of the secondary
outcomes of the trial in an age-specific manner. However, the
primary outcome of proteinuria is based on first morning
Up/c and is not an age-dependent factor.
The trial protocol was based upon assessment of the
literature at the time of study design and feasibility. Genetic
testing was not incorporated into the main trial protocol as
an association between genetic causes of FSGS and treatment
resistance was not defined. Indeed, even now, as genetic
causes of FSGS and other glomerular diseases are identified, it
is evident that some gene mutations cause structural changes
that might not be modifiable, whereas others impact disease
mechanisms that increase the likelihood of a response.
TRPC6 in FSGS might be considered an example.34 Budget-
ary restraints and the absence of a central genetic testing core
with a short turnaround time were the major barriers to the
inclusion of genetic testing as a prerandomization criterion.
In conclusion, this report provides a basis for comparison
with other primary FSGS patient cohorts and clinical trials.
The impact of steroid-resistant FSGS on patient-reported
QOL is significant and comparable in magnitude with that in
children and adults with ESKD.
MATERIALS AND METHODS
Trial design
The FSGS CT was a multicenter, prospective, controlled, open-label
randomized trial comparing two treatment regimens: CSA and MMF/
oral dexamethasone pulses. CSA was designated as the control arm
based on the results of previous clinical trials.14,15 Dexamethasone in
combination with MMF was considered the experimental therapy. The
treatment schedules were guided by published reports and abstracts
detailing the use of the agents chosen for evaluation.14,16
The organization of the project included a Data Coordinating
Center at the Cleveland Clinic and three core coordinating centers—
State University of New York-Stony Brook Health Sciences Center,
University of North Carolina, and Children’s Hospital at Montefiore.
In all, 104 sites received the approval of the institutional review
board and patients were enrolled at 67 participating centers. At the
53 sites where at least 1 patient was randomized, 25 managed only
pediatric patients, 10 only adults, and 18 both.
Inclusion criteria. Patients were eligible if they had primary
FSGS confirmed by central pathology committee review of stored
kidney biopsy material, age of proteinuria onset and current age
between 2 and 40 years, eGFRX40ml/min per 1.73m2 assessed at a
single study visit, Up/c 41 g/g based on an average of 2 first
morning samples collected at least 24 h apart, and resistance to
corticosteroid therapy. If the 2 Up/c results were different by450%,
a third first morning urine sample was collected and the results
included in the average baseline Up/c to increase the stability of the
baseline Up/c. There was no requirement for hypoalbuminemia or
edema and, therefore, patients were not categorized as nephrotic
versus non-nephrotic. Steroid resistance was defined as failure to
achieve a sustained Up/c p1.0 g/g based on at least one treatment
course with steroids before randomization that satisfied both of the
following conditions: (1) minimal treatment duration of 4 weeks
and (2) minimum cumulative dose of 56mg/kg or 1680mg of
prednisone equivalent. The definition of steroid resistance was
weighted toward the pediatric practice in which corticosteroid use is
more uniform and better quantitated. Because the use of steroids is
more variable in adult patients (dose and duration of treatment), a
lower limit of steroid exposure was used to define resistance to
therapy in adults to minimize potential patient exclusion from the
study. The patients with the Up/c between 1 and 1.99 g/g had a level
of proteinuria that persisted despite steroid therapy and were
considered steroid resistant.
The initial criterion of proteinuria was 2 g/g Up/c as this reflects
the diagnostic value for nephrotic-range proteinuria in children.
This value was chosen instead of 3.5 g protein/day in a 24 h urine or
Up/c of 3.5 g/g, a standard used in many adult studies, because it
was anticipated that the majority of study patients would be in the
pediatric age range. The Up/c eligibility criterion was reduced from
2 to 1 g/g during the study because the majority of site investigators
viewed persistent proteinuria as indicative of serious disease and as a
risk factor for progressive CKD. A small number of patients with
Up/c values between 1.0 and 1.99 g/g were excluded before the
change in eligibility criteria.
It is important to note that although the entry criterion for
proteinuria was lowered from 2 to 1 g/g, the patients still required a
50% reduction in proteinuria from the baseline value to qualify for a
partial remission and Up/c o0.2 g/g to achieve a complete
remission. In addition, patients with the lower level of proteinuria
were randomly assigned to a treatment arm. Thus, although this
protocol change represented a potential flaw in design, it did not
compromise the validity of the planned statistical methods.
Subgroup analysis of these patients will be incorporated into the
primary outcome report.
Stored kidney biopsy slides were submitted to a FSGS CT central
pathologist. If the material was read as inconsistent with primary
FSGS, then a second central pathologist reviewed the material.
Agreement between two central pathologists was required to exclude
a subject. The type of primary FSGS was classified according to the
FSGS Columbia Criteria.35
Exclusion criteria. Patients were ineligible if they had second-
ary FSGS; had received previous therapy with sirolimus, CSA,
tacrolimus, MMF, or azathioprine; were treated with cyclopho-
sphamide, chlorambucil, levamisole, methotrexate, or nitrogen
mustard within 30 days of enrollment; received 43 pulses of
methylprednisolone; or were allergic to the study medications.
Remote exposure to cytotoxic agents for frequently relapsing or
steroid-dependent nephrotic syndrome before the onset of steroid
resistance was permitted because it was unlikely to change to
response pattern to the randomized treatment arm. History of
previous cytotoxic therapy was not collected. Additional exclusion
criteria included: obesity (based on estimated dry weight at onset of
disease before steroid therapy) defined as (1) body mass index
497th percentile for patients aged 2–20 years or (2) body mass
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index 440 kg/m2 for patients X21 years old; absolute neutrophil
count o2000/mm3; hematocrit o28%; uncontrolled hypertension
defined as blood pressure 4140/95 for adults or 495th percentile
for age/height for children o18 years of age, while receiving X4
antihypertensive agents; diabetes mellitus; active or serious infec-
tion; cirrhosis or chronic active liver disease; history of significant
gastrointestinal disorder; organ transplantation; history of malig-
nancy; or participation in another therapeutic trial within 30 days
before randomization. Women were excluded if they were lactating,
pregnant, or were of child-bearing age and refused birth control.
Equations and instruments. GFR was estimated using the
Schwartz formula for participants o18 years and Cockroft–Gault
formula for participantsX18 years adjusted for body surface area.36,37
Questionnaires included a patient symptom checklist, family history,
and a QOL assessment. The Short Form-36 (SF-36) was administered
to adults,38,39 and PedsQL (Pediatric Quality of Life Inventory) self-
report was used for children aged 5–17 years and parent proxy-reports
for aged 2–17 years.20 The validity of the SF-36 has been established in
adults with ESKD with reliability coefficients of 0.77–0.93.38,39 The
PedsQL has been validated in general and chronic illness populations
including ESKD with an internal consistency reliability of X0.8.20,21
QOL was assessed at weeks 0, 26, 52, and 78. Only the baseline QOL
assessment was evaluated for this analysis.
Hypertension was defined as a history of hypertension at study
entry or a measured blood pressure 495th percentile for age,
height, and gender for children or 4140/95 for adults. These
definitions were derived from the trial inclusion criteria.
Randomization. The randomization schedules were prepared
by the Data Coordinating Center. Study investigators were blinded
to the randomization allocation schedules. Allocation to the two
treatment groups was designed to be equal and stratified by Core
Coordinating Center, baseline eGFR (o90 vs X90ml/min per
1.73m2) and participant’s self-reported race (black vs non-black).
Randomly permuted blocks of random sizes were used to help
balance numbers of participants assigned to the two treatment
regimens.
Experimental intervention. The study intervention included
immunomodulating therapy for 12 months and renin–angiotensin
blockade for 18 months. The control arm involved treatment with
CSA, 5–6mg/kg per day, divided into two doses (maximum 250mg/
day). The CSA dose was adjusted based on drug levels determined
by high-performance liquid chromatography methods to achieve a
12-h trough concentration between 100 and 250 ng/ml. The
experimental arm comprised treatment with MMF and oral
dexamethasone. The MMF dose was 25–36mg/kg per day, divided
into two daily doses (maximum 2 g/day). The starting MMF dose
was 0.5–0.67 of the full dose for 2 weeks before advancing to the full
dose. The dexamethasone dose was 0.9mg/kg (maximum 40mg)
given as a single dose on two consecutive days, weekly during weeks
1–8; every other week during weeks 10–26; and every 4 weeks during
weeks 30–50, for a total of 46 doses.
Common therapy. Participants assigned to either study group
were treated with prednisone (prednisolone in children requiring a
liquid formulation), 0.3mg/kg (maximum 15mg), every other day
for the first 6 months of treatment. The angiotensin-converting
enzyme inhibitor lisinopril was prescribed in an escalating dose over
4 weeks, from 0.1 to 0.2 and then to 0.4mg/kg/day (maximum 10,
20, and 40mg, respectively). Participants who were intolerant of
angiotensin-converting enzyme inhibitor received the angiotensin
receptor blocker losartan, 0.5mg/kg (maximum 50mg) escalating to
1mg/kg after 2 weeks (maximum 100mg). Participants were not
given an angiotensin-converting enzyme inhibitor and angiotensin
receptor blocker simultaneously during the treatment phase.
Monitoring schedule. Eligibility was confirmed at the screen-
ing visit after review of laboratory and pathology data review before
randomization. Treatment was initiated after the baseline visit (week
0), and subsequent visits occurred at weeks 2, 4, 6, 8, 14, 20, 26, 32,
38, 44, 52, 65, and 78. Long-term monitoring visits were conducted
at 6-month intervals until study closeout.
Outcome measures. The primary outcome was based on
achievement of remission of proteinuria during the first 52 weeks
after randomization. A partial remission was defined as X50%
decline in Up/c, calculated as the mean of two baseline measure-
ments, to a level between 0.2 and 2.0 g/g. A complete remission was
defined as Up/c p0.2 g/g. Patients were categorized by level and
persistence of proteinuria reduction using the Up/c values from all
study visits (Figure 2). The main secondary outcome was persistence
of the reduction in proteinuria after withdrawal of immuno-
suppressive agents, based on the level of proteinuria during
weeks 52–78. A relapse was defined as a complete remission
(Up/co0.2 g/g) followed by the occurrence of a Up/c42.0 g/g or a
partial remission (Up/c of 0.2–2.0 g/g and o50% of baseline value)
followed by the occurrence of a Up/c 42.0 g/g, which is twofold
greater than the nadir of the Up/c documented by the central
laboratory. Additional secondary outcomes were QOL assessed
using SF-36 for adults and PedsQL for children, adverse events, and
preservation of kidney function. Clinical sites were not blinded to
the results of the central Up/c measurements for individual subjects
under their care. Study investigators were blinded to the results of
interim analyses.
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Figure 2 | Focal Segmental Glomerulosclerosis (FSGS) Clinical
Trial primary outcome definitions. Category 1, patients who
achieved a complete remission by week 26 that was sustained to
week 52; category 2, patients who achieved a partial remission at
week 26 and then a complete remission at week 52; category 3,
patients who achieved a partial remission by week 26 that was
sustained to week 52; category 4, patients who achieved a partial
remission at week 26 and then had recurrence of proteinuria
before week 52; category 5, patients who achieved a partial
remission before week 26 and then had a recurrence of
proteinuria before week 26; category 6, patients who never had a
urine protein/creatinine ratio (Up/c) o50% of the baseline value
and an absolute value below 2g/g. Participants with a baseline
Up/c between 1 and 1.99 g/g were required to meet the 50%
reduction in Up/c to meet the criteria of partial remission and
o0.2 g/g for complete remission consistent with subjects
entering with a baseline Up/c X2 g/g.
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Statistical analysis of baseline manuscript. This report of
baseline characteristics of FSGS CT participants utilizes descriptive
statistics, including medians and interquartile range, means, s.d.,
and ranges for continuous variables and percentage of patients for
categorical variables. Analysis of variance, t-tests, w2 tests (when
sample size was45 in all subgroups), and Fisher’s exact tests (when
sample size was p5 in one or more subgroups) were used as
appropriate to compare mean values for continuous variables and
proportions for categorical variables. Regression analyses were
performed on a comparison-wise basis without adjustment for
multiple comparisons. QOL scores for FSGS CT participants were
compared with published data from the general US population and
from patients with ESKD using two-sample t-tests.20–23
Analysis plans and power calculations for the FSGS CT
Statistical analysis plans for the primary and secondary outcomes
were defined before initiation of recruitment. The intent-to-treat
primary statistical analysis will compare the six-level ordered
categorical variable characterizing status during the first year of
follow-up (Figure 2) between the treatment groups. The six levels
will be assigned scores ranging from 1 (for the most favorable
category) to 6 (for the least favorable category). The mean response
score will be compared between the CSA and MMF/dexamethasone
groups within each of the four randomization strata defined by
baseline eGFR (GFR o90 vs X90ml/min per 1.73m2) and race
(black vs non-black). A related five-level ordered outcome was used
at week 78. The six-level ordered categorical variable characterizing
the study outcome represents a new approach to assessing changes
in proteinuria over time during the trial and has no precedent in the
literature.
The FSGS Clinical Trial was originally designed to randomize 500
patients with equal allocation to the CSA and MMF/dexamethasone
groups. Because existing data did not allow the remission rate to be
forecast reliably, power calculations were performed assuming
combined partial and complete remission probabilities scenarios
ranging from 32.5 to 60.0% in the CSA control arm. The study’s
original design with 500 randomized patients would have provided
80% power at a two-sided a-level of 5% to detect an absolute
increase in remission probability ranging from 10.8% (from 32.5 to
43.3%) to 11.5% (from 60 to 70.5%) under these remission rate
scenarios. The analysis incorporates the score for the primary
outcome based on the six-level ordered categorical variable. Efforts
for enrollment resulted in a pool of 192 subjects, from which 138
subjects meeting eligibility criteria were randomized. The final
sample size of 138 randomized patients provided 80% power at the
a-level of 5% to detect an absolute increase in the probability of
remission ranging from 20.9% (from 32.5 to 53.4%) to 18.2% (from
60.0 to 78.2%) under the same scenarios.
Ethics. This study was registered in clinicaltrials.gov, identifier
NCT00135811, and monitored by a Data and Safety Monitoring
Board. The study protocol was reviewed and approved by the
institutional review board at each participating site. Informed
consent and, when appropriate, assent was obtained before
enrollment.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This study was sponsored by the NIH/NIDDK grants U01—DK063385,
DK063490, DK063455, and DK063549. A portion of the pediatric
quality-of-life data were previously published in an abstract form by
the American Society of Nephrology Renal Week, 2009. This study
represents the participation of the following institutions and
investigators: Anjali Acharia, Jacobi Medical Center; Steven Alexander,
Stanford Children’s Hospital; Amira Al-Uzri, Doernbecher Children’s
Hospital, Oregon; Sharon Andreoli, Indiana University Riley Hospital;
Gerald Appel, Columbia University Presbyterian Medical Center
–Internal Medicine; Mazen Arar, University of Texas Health Science
Center at San Antonio; Bettina Ault, University of Tennessee Health
Science, Memphis; William Baker, Blue Ridge Nephrology Associates;
Noosha Baqi, Saint Barnabas Medical Center, NJ; Sharon Bartosh,
University of Wisconsin; Lorraine Bell, Montreal Children’s Hospital;
Nadine Benador, University of California San Diego; Corrine
Benchimol, Mount Sinai School of Medicine–Peds; Mark Benfield,
University of Alabama at Birmingham; Danilo Bernardo, Valley
Hypertension Nephrology; Phillip Berry, Specially for Children;
Andrew Bland, Renalcare Associates of Peoria, IL; Tom Blydt-Hansen,
Children’s Hospital, Winnipeg; Karl Brandspigel, Albemarle
Nephrology Associates; Milos Budisavljevic, Medical University of
South Carolina; Brad Carter, Kidney Specialists of Central Oklahoma;
Daniel Cattran, Toronto General Hospital; Deepa Chand, Cleveland
Clinic; Chandran Chandra, St Joseph Regional Medical Center; Kaye
Christopher, Nephrology Associates of Hartsville; Howard Corey,
Morristown Memorial Hospital, NJ; Eileen Ellis, Arkansas Children’s
Hospital; Demetrius Ellis, Children’s Hospital of Pittsburgh; Babatunde
Fariyike, Babatunde Fariyike Nephrology; Robert Fildes, Fairfax
Hospital for Children; Elie Firzli, St Joseph’s Hospital and Medical
Center; Danny Fischer, Kidney and Hypertension Center, Cincinnati;
Joseph Flynn, Children’s Hospital, Seattle; John Foreman, Duke
University Medical Center–Peds; Susan Furth, Johns Hopkins
Pediatrics Nephrology; Debbie Gipson, University of North Carolina,
Chapel Hill; Larry Greenbaum, Emory University; Ted Groshong,
University of Missouri–Columbia; Anne Guillot, University of Vermont;
Robert A. Gutman, Durham Nephrology; German Hernandez, Texas
Tech University Health Sciences Center; Jeffrey Hoggard, Eastern
Nephrology Associates; Robert Holleman, University of South
Carolina; Mohammad Ilyas, University of Florida Jacksonville; J. Ashley
Jefferson, University of Washington Medical Center; Eunice John,
University of Illinois at Chicago; Valerie Johnson, Cornell Medical
College New York Presbyterian Hospital; Joshua Kaplan, University of
Medicine and Dentistry of New Jersey; Frederick Kaskel, Montefiore
Medical Center; Michelle Krause, University of Arkansas, Internal
Medicine Nephrology; Juan Kupferman, Maimonides Medical Center;
Marc Lande, University of Rochester; Jerome Lane, Children’s
Memorial Hospital, Chicago; Gary Lerner, Children’s Hospital Los
Angeles; Jen-Jar Lin, University of Michigan; John Mahan, Ohio State
University–Peds; Susan Massengill, Carolinas Medical Center–Peds;
Douglas Matsell, Children’s Hospital British Columbia; Tej Mattoo,
Children’s Hospital of Michigan; Lawrence Mcgee, Spartanburg
Nephrology; Susan Mendley, University of Maryland Hospital; Richard
Merrill, Kidney Center, Greenville, NC; John Middleton, Duke
University Medical Center–Internal Medicine; Julian Midgley, Alberta
Children’s Hospital; Asha Moudgil, Children’s National Medical Center;
Dianne Muchant, University of Louisville; Jerome Murphy, Children’s
Hospital Central California; James Musgrave, University of Hawaii
School of Medicine; Martin Nash, Columbia University Babies’ And
Children’s Hospital; Richard Neiberger, University of Florida,
Gainesville; Victoria Norwood, University of Virginia Children’s
Medical Center; Luis Ortiz, Medical College of Georgia; Cynthia Pan,
Children’s Hospital of Wisconsin; Ana Paredes, Miami Children’s
Hospital; Rupal Patel, Baylor College of Medicine–Internal Medicine;
Dechu Puliyanda, Cedars-Sinai Medical Center; Majid Rasoulpour,
Connecticut Children’s Medical Center; Shobha Sahney, Loma Linda
University; Virginia Savin, Medical College of Wisconsin; Jon
Scheinman, University of Kansas; Jeffrey Schelling, Case Western
Reserve University, Internal Medicine, Nephrology; Morris
Schoeneman, Suny Health Sci Center at Brooklyn; Mouin Seikaly,
684 Kidney International (2011) 79, 678–685
or ig ina l a r t i c l e DS Gipson et al.: FSGS CT baseline cohort
Children’s Medical Center of Dallas; Muhammed Shakeel, Nephrology
and Internal Medicine, Anderson, SC; Ganesh Shidham, Ohio State
University Medical Center; Ajay Singh, Brigham and Women’s
Hospital; Michael Somers, Children’s Hospital Boston; James
Springate, Women’s and Children’s Hospital of Buffalo; Frederic Strife,
Cincinnati Children’s Hospital Medical Center; Rita Swinford,
University of Texas Southwestern Houston–Internal Medicine; Howard
Trachtman, Cohen Children’s Medical Center, NY; Martin Turman,
University of Oklahoma Health Sciences Center; Matti Vehaskari,
Children’s Hospital, New Orleans; Brad Warady, Children’s Mercy
Hospital, Kansas City, MO; Steven Wassner, Penn State Children’s
Hospital; Lynne Weiss, Robert Wood Johnson Medical School, NJ;
Robert Weiss, Westchester Medical Center, NY; Dilys Whyte, SUNY at
Stony Brook; Craig Wong, UNM Children’s Hospital; Ellen Wood,
Cardinal Glennon Children’s Hospital in St Louis; Jonathon Woods,
Southeastern Neph Associates Wilmington; Ora Yadin, Mattel’s
Children’s Hospital UCLA; Verna Yiu, University of Alberta Pediatric
Nephrology, Edmonton; Gaston Zilleruelo, University of Miami.
REFERENCES
1. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the
podocytopathies: a reassessment of the primary nephrotic diseases. Clin J
Am Soc Nephrol 2007; 2: 529–542.
2. Barisoni L, Schnaper HW, Kopp JB. Advances in the biology and genetics
of the podocytopathies: implications for diagnosis and therapy. Arch
Pathol Lab Med 2009; 133: 201–216.
3. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental
glomerulosclerosis. Semin Nephrol 2003; 23: 147–160.
4. Chun MJ, Korbet SM, Schwartz MM et al. Focal segmental
glomerulosclerosis in nephrotic adults: presentation, prognosis, and
response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15:
2169–2177.
5. Thomas DB, Franceschini N, Hogan SL et al. Clinical and pathologic
characteristics of focal segmental glomerulosclerosis pathologic variants.
Kidney Int 2006; 69: 920–926.
6. Rydel JJ, Korbet SM, Borok RZ et al. Focal segmental glomerular sclerosis
in adults: presentation, course, and response to treatment. Am J Kidney
Dis 1995; 25: 534–542.
7. Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for
focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev
2008; (3): CD003233.
8. Abrantes MM, Cardoso LSB, Lima EM et al. Predictive factors of chronic
kidney disease in primary focal segmental glomerulosclerosis. Pediatr
Nephrol 2006; 21: 1003–1012.
9. Moranne O, Watier L, Rossert J et al. Primary glomerulonephritis: an
update on renal survival and determinants of progression. QJM 2008;
101: 215–224.
10. Alexopoulos E, Stangou M, Papagianni A et al. Factors influencing the
course and the response to treatment in primary focal segmental
glomerulosclerosis. Nephrol Dial Transplant 2000; 15: 1348–1356.
11. Bakir AA, Share DS, Levy PS et al. Focal segmental glomerulosclerosis in
adult African Americans. Clin Nephrol 1996; 46: 306–311.
12. Meyrier A. An update on the treatment options for focal segmental
glomerulosclerosis. Expert Opin Pharmacother 2009; 10: 615–628.
13. Fernandez-Fresnedo G, Segarra A, Gonzalez E et al. Rituximab treatment
of adult patients with steroid-resistant focal segmental
glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4: 1317–1323.
14. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine
in patients with steroid-resistant focal segmental glomerulosclerosis.
North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56:
2220–2226.
15. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled
trial of cyclosporine in steroid-resistant idiopathic focal segmental
glomerulosclerosis in children. J Am Soc Nephrol 1996; 7: 56–63.
16. Smith D, Branton M, Fervenza F et al. Pulse dexamethasone for focal
segmental glomerulosclerosis. J Am Soc Nephrol 2003; 13: 526a.
17. Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome:
regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:
824–832.
18. Nayagam LS, Ganguli A, Rathi M et al. Mycophenolate mofetil or standard
therapy for membranous nephropathy and focal segmental
glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008; 23:
1926–1930.
19. Cattran DC, Wang MM, Appel G et al. Mycophenolate mofetil in the
treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62:
405–411.
20. Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of
life in children and adolescents with chronic conditions: a comparative
analysis of 10 disease clusters and 33 disease categories/severities
utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes
2007; 5: 43.
21. Goldstein SL, Graham N, Warady BA et al. Measuring health-related
quality of life in children with ESRD: performance of the generic and
ESRD-specific instrument of the Pediatric Quality of Life Inventory
(PedsQL). Am J Kidney Dis 2008; 51: 285–297.
22. Unruh M, Benz R, Greene T et al. Effects of hemodialysis dose and
membrane flux on health-related quality of life in the HEMO Study. Kidney
Int 2004; 66: 355–366.
23. Ware J, Kosinski M, Gandek B. SF-36 Health Survey: Manual and
Interpretation Guide. Quality Metric Incorporated: Lincoln, RI, 2003.
24. Dragovic D, Rosenstock JL, Wahl SJ et al. Increasing incidence of focal
segmental glomerulosclerosis and an examination of demographic
patterns. Clin Nephrol 2005; 63: 1–7.
25. Boyer O, Moulder JK, Somers MJG. Focal and segmental
glomerulosclerosis in children: a longitudinal assessment. Pediatr Nephrol
2007; 22: 1159–1166.
26. Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor
marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005; 20:
707–711.
27. Mapes DL, Bragg-Gresham JL, Bommer J et al. Health-related quality of
life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J
Kidney Dis 2004; 44: 54–60.
28. Gerson AC, Wentz A, Abraham AG et al. Health-related quality of life of
children with mild to moderate chronic kidney disease. Pediatrics 2010;
125: 349–357.
29. Han SS, Kim KW, Na KY et al. Quality of life and mortality from a
nephrologist’s view: a prospective observational study. BMC Nephrol
2009; 10: 39.
30. Rizk D, Jurkovitz C, Veledar E et al. Quality of life in autosomal dominant
polycystic kidney disease patients not yet on dialysis. Clin J Am Soc
Nephrol 2009; 4: 560–566.
31. Ruth E-M, Landolt MA, Neuhaus TJ et al. Health-related quality of life and
psychosocial adjustment in steroid-sensitive nephrotic syndrome.
J Pediatr 2004; 145: 778–783.
32. Paniagua R, Amato D, Vonesh E et al. Health-related quality of life predicts
outcomes but is not affected by peritoneal clearance: the ADEMEX trial.
Kidney Int 2005; 67: 1093–1104.
33. Mujais SK, Story K, Brouillette J et al. Health-related quality of life in CKD
patients: correlates and evolution over time. Clin J Am Soc Nephrol 2009;
4: 1293–1301.
34. Winn MP. Not all in the family: mutations of podocin in sporadic
steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13:
577–579.
35. D’Agati VD, Fogo AB, Bruijn JA et al. Pathologic classification of focal
segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;
43: 368–382.
36. Schwartz GJ, Haycock GB, Edelmann CM et al. A simple estimate of
glomerular filtration rate in children derived from body length and
plasma creatinine. Pediatrics 1976; 58: 259–263.
37. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum
creatinine. Nephron 1976; 16: 31–41.
38. Meyer KB, Espindle DM, DeGiacomo JM et al. Monitoring dialysis patients’
health status. Am J Kidney Dis 1994; 24: 267–279.
39. Kurtin PS, Davies AR, Meyer KB et al. Patient-based health status measures
in outpatient dialysis. Early experiences in developing an outcomes
assessment program. Med Care 1992; 30: 136–149.
Kidney International (2011) 79, 678–685 685
DS Gipson et al.: FSGS CT baseline cohort o r ig ina l a r t i c l e
